The drug, acetazolamide, sold under the trade name Diamox, is "cheap to make, easy to take and has limited side effects," said Bahktiar Yamini, a professor at the University of Chicago Medicine in the US.
"We tested this combination treatment strategy in several animal models," Yamini said.
It cured some of them. Others had a 30 to 40 per cent increase in survival time, researchers said.
When Yamini and colleagues looked at BCL-3 level from previous human studies, they found that patients with lower levels of BCL-3 who were treated with TMZ survived longer than patients who had high levels of this biomarker.
"An important feature of predictors like BCL-3 is that they are informative. They can identify pathways to improve treatment response," the researchers said.
By examining those pathways, the researchers identified carbonic anhydrase inhibitors, such as acetazolamide, as a way to reduce resistance to temozolomide.
"Our data," they note, demonstrate that it is the "induction of CAII by TMZ that is important in modulating response to therapy."
Validating the use of BCL-3 to predict which patients will benefit from the use of temozolomide will require verification in a prospective randomised clinical trial, the researchers note.
They also suggest that repurposing acetazolamide along with temozolamide might be particularly effective in a subgroup of appropriate patients with tumours that have high BCL-3 expression.
(This story has not been edited by Business Standard staff and is auto-generated from a syndicated feed.)